IIIF provides researchers rich metadata and media viewing options for comparison of works across cultural heritage collections. Visit the IIIF page to learn more.
RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)-- Merck (MRK), known as MSD outside of the United States and Canada, and Eisai today announced results from the Phase 3 LEAP-012 trial evaluating KEYTRUDA ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced results from the Phase 3 LEAP-012 trial evaluating KEYTRUDA ® (pembrolizumab), Merck’s anti-PD-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback